Clinical Report: Worldwide Impact of Pain Associated with Malignant Bone Tumors
Overview
This meta-analysis evaluates the global burden of pain in malignant bone tumors, focusing on the effectiveness of pain management interventions.
Background
Malignant bone tumors are associated with severe pain and significant loss of quality of life for patients. Effective pain management is crucial. Current treatment options include radiotherapy and bone-modifying agents.
Data Highlights
Intervention
Standardized Mean Difference (SMD)
95% Confidence Interval (CI)
One-time EBRT
0.04
-0.02–0.1
Denosumab vs. Zoledronic Acid
0.01
-0.02–0.05
Bisphosphonates Alone
0.12
0.05–0.2
Short-course Radiotherapy (≤1 week)
0.05
0.05–0.05
Key Findings
Malignant bone tumors are a leading cause of severe pain in cancer patients.
Radiotherapy effectively manages pain.
Bone-modifying agents show variable efficacy.
Short-course radiotherapy has a positive but negligible impact on pain management.
Most studies included in the analysis were of fair to good quality.
Clinical Implications
Monitoring for potential side effects, such as renal function impairment and osteonecrosis of the jaw, is essential.
Conclusion
The findings indicate the use of radiotherapy and bone-modifying agents for managing pain and preventing skeletal-related events in patients with malignant bone tumors.
